Click HERE to download the PDF version

INTRODUCTION

In the current pharmaceutical market, it is imperative to hasten the development of new active molecules and expediting their products time-to-market. Today, there is an immense pressure on medicinal chemists to synthetize new active compounds and also on process chemists to develop a scalable synthesis. A confluence of factors is driving the need for a paradigm shift in pharmaceutical manufacturing strategies in order to accelerate R&D pipeline to market. Movement towards rising generics competition, dramatically higher clinical trial costs and timelines, the shift away from blockbusters to niche products, and the growing number of candidates with accelerated development designations (Fast Track, Breakthrough Therapy, Orphan Drug) are all placing pressure on drug manufacturers to eliminate inefficiencies and inc ...